User profiles for Lars Weidolf
Lars WeidolfVerified email at astrazeneca.com Cited by 4865 |
Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole
…, G Hasselgren, K Röhss, L Weidolf - Clinical …, 2001 - Springer
This article reviews the pharmacokinetics of esomeprazole, the (S)-isomer of the proton pump
inhibitor (PPI) omeprazole. Esomeprazole is the first single isomer PPI developed for the …
inhibitor (PPI) omeprazole. Esomeprazole is the first single isomer PPI developed for the …
State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications
…, K Nilsson, F Raubacher, L Weidolf - Drug metabolism …, 2007 - Taylor & Francis
In drug design, it is crucial to have reliable information on how a chemical entity behaves in
the presence of metabolizing enzymes. This requires substantial experimental efforts. …
the presence of metabolizing enzymes. This requires substantial experimental efforts. …
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome …
XQ Li, TB Andersson, M Ahlström, L Weidolf - Drug metabolism and …, 2004 - ASPET
The human clearance of proton pump inhibitors (PPIs) of the substituted benzimidazole
class is conducted primarily by the hepatic cytochrome P450 (P450) system. To compare the …
class is conducted primarily by the hepatic cytochrome P450 (P450) system. To compare the …
Stereoselective disposition of proton pump inhibitors
T Andersson, L Weidolf - Clinical Drug Investigation, 2008 - Springer
It is estimated that about half of all therapeutic agents are chiral, but most of these drugs are
administered in the form of the racemic mixture, ie a 50/50 mixture of its enantiomers. …
administered in the form of the racemic mixture, ie a 50/50 mixture of its enantiomers. …
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
…, M Antonsson, AK Naudot, I Skånberg, L Weidolf - Drug Metabolism and …, 2000 - ASPET
This study demonstrates the stereoselective metabolism of the optical isomers of omeprazole
in human liver microsomes. The intrinsic clearance (CL int ) of the formation of the hydroxy …
in human liver microsomes. The intrinsic clearance (CL int ) of the formation of the hydroxy …
Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies
…, GN Nilsson, RA Thompson, L Weidolf - Chemical research in …, 2012 - ACS Publications
As part of the drug discovery and development process, it is important to understand the fate
of the drug candidate in humans and the relevance of the animal species used for …
of the drug candidate in humans and the relevance of the animal species used for …
Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions
U Jurva, HV Wikström, L Weidolf… - … in mass spectrometry, 2003 - Wiley Online Library
The extent to which electrochemistry on‐line with electrospray mass spectrometry can be
used to mimic cytochrome P450 catalyzed oxidations has been investigated. Comparisons on …
used to mimic cytochrome P450 catalyzed oxidations has been investigated. Comparisons on …
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
RA Thompson, EM Isin, Y Li, L Weidolf… - Chemical research in …, 2012 - ACS Publications
Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clinically
significant toxicities leading to attrition during drug development as well as postlicensing …
significant toxicities leading to attrition during drug development as well as postlicensing …
Mimicry of phase I drug metabolism–novel methods for metabolite characterization and synthesis
T Johansson, L Weidolf, U Jurva - Rapid Communications in …, 2007 - Wiley Online Library
The extent to which electrochemical oxidation, electrochemically assisted Fenton chemistry
and synthetic metalloporphines can be used to mimic cytochrome P450 catalyzed oxidations …
and synthetic metalloporphines can be used to mimic cytochrome P450 catalyzed oxidations …
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
…, EM Isin, Y Li, R Weaver, L Weidolf… - Chemico-biological …, 2011 - Elsevier
Drug toxicity is a leading cause of attrition of candidate drugs during drug development as
well as of withdrawal of drugs post-licensing due to adverse drug reactions in man. These …
well as of withdrawal of drugs post-licensing due to adverse drug reactions in man. These …